As World Health Organisation (WHO) declares monkeypox a global health emergency, Bavarian Nordic’s vaccine receives approval in Europe a month after the company applied for extended label. Nordic’s Jynneos is already in use in the US for the purpose of combating monkeypox. The approval in Europe will enable speedy prevention from monkeypox, unlike the usual timeline of six to nine months. Though monkeypox is a threat everywhere, Europe has a slightly higher rate than the rest of the world, which is why WHO has urged healthcare providers to protect vulnerable and affected groups from the disease.
Read More from FiercePharma